Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.125 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.125 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.125 | 1 | 0.5 |
Treponema pallidum | flavodoxin | 0.0478 | 0 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.062 | 0.1841 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.125 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.125 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.125 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0478 | 0 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0478 | 0 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.063 | 0.1964 | 0.0151 |
Giardia lamblia | Hypothetical protein | 0.1108 | 0.8159 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.125 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0478 | 0 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.125 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.125 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.125 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.125 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.125 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.1108 | 0.8159 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.125 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0772 | 0.3805 | 0.3805 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.125 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.125 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0478 | 0 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0478 | 0 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.125 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0772 | 0.3805 | 0.2407 |
Plasmodium vivax | flavodoxin domain containing protein | 0.1108 | 0.8159 | 0.8159 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.125 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.125 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0772 | 0.3805 | 0.5 |
Leishmania major | cytochrome P450 reductase, putative | 0.1108 | 0.8159 | 0.8159 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.062 | 0.1841 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.125 | 1 | 1 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.1108 | 0.8159 | 0.8159 |
Leishmania major | p450 reductase, putative | 0.125 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0772 | 0.3805 | 0.3805 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.125 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.125 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.